[Mucoregulatory therapy in secreting disease of the middle ear].
A controlled double-blind study was carried out vs placebo to evaluate the preventive and therapeutic efficacy of carboxymethylcysteine lysine salt (SCMC-Lys) in 40 non-adenoidectomised children (aged between 6-7 years old) with secretive otitis media and in 30 adult patients with acute inflammatory pathologies of the middle ear. The drug SCMC-Lys was administered to children at a dose of 750 mg/die in a linctus formula for 10 days and 2.7 g in a granular formula once a day for a maximum of 15 days if recovery had not already occurred. All subjects were assessed before and after treatment by means of an anamnestic and objective otological examination, tympanometry, nephelometric tests for IgA and mucociliary transport time. SCMC-Lys eliminated hypoacoustic symptoms in 85% of children treated with SCMC-Lys and in 35% of those treated with placebo.
Bonci
M
M
Divisione di Otorinolaringoiatria, Ospedale Civile E Agnelli, Pinerolo, Torino.
Bozzi
A
A
D000158:Acoustic Impedance Tests; D000328:Adult; D002233:Carbocysteine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D034381:Hearing Loss / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D010034:Otitis Media with Effusion / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D005100:Expectorants; C034932:carbocysteine-lysine; D002233:Carbocysteine
Terapia mucoregolatrice nella patologia secernente dell'orecchio medio.